Business Context and Reporting Period
Company: Ocular Therapeutix, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 9, 2016
Reporting Period: Quarter ended September 30, 2016
Context: The Company filed this report to announce its financial results for the third quarter of 2016. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided Form 8-K text serves as a cover document referencing a press release (Exhibit 99.1) for specific data. The filing text itself does not provide clear values for the following metrics:
- Revenue: Not stated in the filing text.
- Profit/Loss: Not stated in the filing text.
- Cash Flow: Not stated in the filing text.
- Margins: Not stated in the filing text.
- Debt and Liquidity: Not stated in the filing text.
Material Changes
The filing text does not contain specific numerical comparisons or descriptions of material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for this information.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. These disclosures are expected to be found within the referenced press release.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 9, 2016) for actual revenue, net loss, and cash position figures.
- Verify the Company's cash runway and burn rate as disclosed in the press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm if the Company provided updated financial guidance for the full year 2016.